Lund-based specialty pharmaceutical company founded in 1991 and listed on Nasdaq Stockholm, built on the proprietary FluidCrystal technology that converts drugs into long-acting depot injections. Led since 2003 by president and CEO Fredrik Tiberg and employing around 290 people, Camurus’s lead product is Buvidal, the weekly/monthly injectable for opioid dependence. In Portugal it operates through Camurus, Unipessoal, Lda.
Camurus’s Portuguese presence runs through Camurus, Unipessoal, Lda, its locally registered entity documented in the Swedish Embassy and Luso-Swedish Chamber of Commerce (CLS) catalogue of Swedish investments in Portugal — the commercial infrastructure behind making its long-acting therapies available in the Portuguese health system.
The parent company is one of Skåne’s life-science flagships: founded in Lund in 1991, listed on Nasdaq Stockholm, and led since 2003 by president and CEO Fredrik Tiberg. Its FluidCrystal lipid-based delivery technology turns existing molecules into weekly or monthly depot injections; the lead application, Buvidal, has become a European standard-of-care option in opioid-dependence treatment, and the roughly 290-employee company has continued to report record sales through 2026.
Swedish pharma’s Portuguese commercial entities rarely make headlines, but they are how Nordic clinical innovation actually reaches Portuguese patients — and Camurus, with an addiction-medicine franchise directly relevant to Portugal’s pioneering drug-policy model, is one of the more interesting fits in the corridor.
Fractio helps Nordic companies build the Portuguese relationships, references and operational footprint they need to succeed in Portugal.
Talk to Fractio →